Events

PITTSBURGH, Sept. 11, 2014 /PRNewswire-iReach/ -- Today the FDA announced approval of PleximmuneTM, a blood test from the Pittsburgh-based biotech company Plexision. This test predicts acute cellular rejection of transplanted livers and intestines in children. PleximmuneTM is a first-in-class test to determine a personalized rejection-risk index using cell-based technology.

Plexision’s Pharmacokinetics (PK)/Pharmacodynamics (PD) solutions presented at Cambridge Healthtech Institute’s Immunogenicity Summit in Washington, DC on November 11, 2013.

The Pleximmune test is the first blood test of its kind to predict whether acute cellular rejection will occur in children with liver or intestine transplantation. This information can help transplant physicians guide post-transplant care. During a six-year period, over two hundred and eighty blood samples from more than 200 children were tested in two groups. Samples from the first portion of the study period were termed the training set, and those obtained subsequently were termed the validation set.

The American Transplant Congress was held between May 18-22 in Seattle this year. The American Transplant Congress is the premier venue for scientific exchange between the various disciplines uniquely involved in solid organ transplantation.